Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.68 |
| ▸ | CA1 | P00915 | 5/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671997 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL4054766 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL4054764 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL13330074 | 0.90 | PTPN1 (0.77) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL7363606 | 0.88 | CA2 (0.71) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL5793343 | 0.87 | CA2 (0.69) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL8667639 | 0.87 | CA2 (0.69) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL3404637 | 0.87 | CA2 (0.69) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL8520566 | 0.87 | PTPN1 (0.72) | CA2CA1PTPN1CA12CA9 | |
| SCHEMBL3497780 | 0.87 | PTPN1 (0.72) | CA2CA1PTPN1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-7642250-B2 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642250-B2 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2007038630-A2 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | PPOX, PPIF, COX5A | CA2 4500/4885CA1 4209/4885PTPN1 1541/4885 |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | PPOX, PPIF, COX5A | CA2 4500/4885CA1 4209/4885PTPN1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.